Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-06-21

Clinical Trial Update: 48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection [Phase 2]

View source ↗

Summary

A Phase 2 48-week study in pediatric HIV patients comparing GW433908 with ritonavir versus GW433908 alone; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GW433908
  • Ritonavir (Ritonavir)

Snippet

Sponsor: ViiV Healthcare | Conditions: Infection, Human Immunodeficiency Virus I | Phase 2 | Status: COMPLETED | Results posted: 2012-06-21